Clinical trials: Attention Deficit Disorders With Hyperactivity
ADHD, Attention Deficit Hyperactivity Disorder
Study of Medication Patch to Treat Children Ages 6-12 With ADHD
The purpose of this study is to investigate the effectiveness of a medication skin patch called Methylphenidate Transdermal System (MTS). We will compare the MTS medicated patch to a placebo patch.
- Trial name
- NCT00586157
- Testing
- Methylphenidate Transdermal System
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Attention-Deficit Hyperactivity Disorder (ADHD)
PDC-1421 Treatment in Adult Patients With ADHD
Part II is a double-blind, randomized, parallel-group, placebo-controlled study. The primary objective of this trial is to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD.
- Trial name
- NCT05202327
- Testing
- PDC-1421 Capsule
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 99 people
- Sponsor
- BioLite, Inc.
Attention Deficit Hyperactivity Disorder
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
For children and adolescents, how does SPD503 compare to placebo for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01244490
- Testing
- Extended-release Guanfacine Hydrochloride, Atomoxetine Hydrochloride
- Where
- 66 sites in United States, Austria and 11 more
- Volunteers
- 338 people
- Sponsor
- Shire
Adult Attention Deficit Hyperactivity Disorder
Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening
This is a single-site study. One purpose of this trial is to extend the safety and efficacy evidence basis for Azstarys in adults with ADHD.
- Trial name
- NCT06000501
- Testing
- Serdexmethylphenidate/dexmethylphenidate
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- NYU Langone Health
Attention Deficit Hyperactivity Disorder
Disseminating a Model Intervention to Promote Improved Attention-deficit Hyperactivity Disorder (ADHD) Care in the Community
The American Academy of Pediatrics (AAP) has established a set of consensus guidelines for pediatricians to follow. These guidelines can be challenging to implement in typical community-based practices.
- Trial name
- NCT01056016
- Testing
- ADHD Collaborative
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cognition Disorder, Attention Deficit Disorder
Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
Deficits in memory, attention, cognitive, and executive functions are the most common disabilities after traumatic brain injury (TBI).
- Conditions
- Cognition Disorder, Attention Deficit Disorder, Traumatic Brain Injury
- Trial name
- DAPET-TBI (NCT02225106)
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Pennsylvania
Attention Deficit Disorder With Hyperactivity
Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Trial 42603ATT3004 is an open-label extension study to clinical trial 42603ATT3002 (NCT00246220). In trial 42603ATT3002 the efficacy and safety of OROS methylphenidate was assessed in adult subjects with Attention Deficit…
- Trial name
- NCT00307684
- Testing
- double blind PR OROS methylphenidate, open label PR OROS methylphenidate
- Where
- 21 sites in France, Germany and 5 more
- Volunteers
- 155 people
- Sponsor
- Janssen-Cilag International NV
Attention-Deficit Hyperactivity Disorder
An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
The main purpose of this study is to evaluate the efficacy of JNS001 titrated to daily doses of 18 to 72 mg in adults with attention-deficit hyperactivity disorder (ADHD) relative to placebo.
- Trial name
- NCT01323192
- Testing
- JNS001
- Where
- 30 sites in Japan
- Volunteers
- 284 people
- Sponsor
- Janssen Pharmaceutical K.K.
Attention Deficit Hyperactivity Disorder
PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations
This is PART B of a 2-part, 6-week, double-blind, dose-optimization, parallel-group study in children and adolescents (ages 6-17 years) with ADHD with and without CNVs in specific genes implicated in glutamatergic signaling and…
- Trial name
- NCT03609619
- Testing
- AEVI-001
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Attention Deficit/Hyperactivity Disorder
A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD
The is a multicenter, dose-optimized, open-label, safety/ tolerability and pharmacokinetic (PK) study with Azstarys® in children 4 and 5 years of age with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- KP415P02 (NCT05721235)
- Testing
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
- Where
- 20 sites in United States
- Volunteers
- 123 people
- Sponsor
- Corium, Inc.
Attention Deficit Hyperactivity Disorder
A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
The purpose of the study is to investigate the relationship of changes in measures of academic performance and problem behaviors, to changes in core Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in Asian children…
- Trial name
- NCT00471354
- Testing
- Atomoxetine
- Where
- 8 sites in China, South Korea and 1 more
- Volunteers
- 228 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD)
Children with Attention Deficit Hyperactivity Disorder (ADHD) have numerous areas of neuropsychological dysfunction including response inhibition, working memory, and attention.
- Trial name
- NCT01238822
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention Deficit Disorder With Hyperactivity
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine the effectiveness of behavioral treatment, drug treatment, and combined treatment for children with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00050622
- Testing
- Methylphenidate 0.15 mg/kg, Low-Intensity BMOD, Methylphenidate 0.3 mg/kg
- Where
- 2 sites in United States
- Volunteers
- 154 people
- Sponsor
- Florida International University
ADHD NOS
Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)
This is an open-label study with daily doses up to 144 mg/day Strattera (atomoxetine) in the treatment of adults with attention deficit hyperactivity disorder not otherwise specified.
- Trial name
- NCT00181766
- Testing
- Strattera (atomoxetine)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Disorder With Hyperactivity
Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17
The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.
- Trial name
- NCT00150592
- Testing
- SPD503 (Guanfacine HCl)
- Volunteers
- 182 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
Software Treatment for Actively Reducing Severity of ADHD - Follow Up
This is an exploratory study to assess potential maintenance of clinical benefit (cognition and symptoms) following 4 weeks of at-home digital therapy in ADHD children.
- Trial name
- STARS-ADHD2 (NCT02828644)
- Testing
- EVO
- Where
- 15 sites in United States
- Volunteers
- 175 people
- Sponsor
- Akili Interactive Labs, Inc.
Attention Deficit Disorder With Hyperactivity
Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to assess the safety and tolerability of administering SPD503 (Guanfacine hydrochloride) with psychostimulants (amphetamine or methylphenidate) for treatment of ADHD in children and adolescents aged…
- Trial name
- NCT00151996
- Testing
- Methylphenidate + SPD503 (Guanfacine hydrochloride), Amphetamine + SPD503
- Volunteers
- 75 people
- Sponsor
- Shire
Attention-Deficit Hyperactivity Disorder
Pharmacokinetics of HLD200 in Children and Adolescents With ADHD
This study was designed to assess the pharmacokinetic effects of a single dose of HLD200 (methylphenidate hydrochloride) in children and adolescents with ADHD.
- Trial name
- NCT01907360
- Testing
- HLD200 (methylphenidate hydrochloride)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
ADHD, Substance Use Disorders
Integrated Treatment for Adolescents With ADHD
Attention-Deficit/Hyperactivity Disorder (ADHD) exists in 20-50% of the 3 million adolescents annually enrolled in outpatient mental health and substance use treatment.
- Trial name
- CASALEAP IT2A (NCT02420990)
- Testing
- Medication Integration Protocol (MIP), Changing Academic Support in the Home for Adolescents with ADHD (CASH-AA)
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- The National Center on Addiction and Substance Abuse at Columbia University
Attention Deficit Hyperactivity Disorder, Reading Disabilities
Interventions for Children With Attention and Reading Disorders
The objective of this randomized clinical trial is to address unanswered questions about the relative effectiveness of treatments for children with both Attention Deficit Hyperactivity Disorder (ADHD) and significant reading…
- Trial name
- ICARD (NCT01133847)
- Testing
- Methylphenidate, Intensive reading instruction, Parent Training
- Where
- 2 sites in United States
- Volunteers
- 222 people
- Sponsor
- The University of Texas Health Science Center, Houston